Here you can find information and links to educational seminars and other resources.

EV Flow Cytometry Seminar Series

If you would like to register to the seminar series and gain access to our slack channel ( for questions and offline discussion please complete the following form.


Date: 3rd June 2020 – Register Here –  [08:00 PDT, 11:00 EDT, 17:00 CEST]

Topic: Research Talk

Title: Calibrated flow cytometry study reveals that concentrations of extracellular vesicles decrease after acute myocardial infarction

Moderators: André Görgens [1], Paul Harrison [2]
Karolinska Institute, Sweden [1], University of Birmingham, UK

Speaker: Aleksandra Gąsecka, Medical University of Warsaw, Poland & Amsterdam University Medical Centers, Netherlands

Abstract: Acute myocardial infarction (AMI) is a major cause of human death and disability, but early biomarkers for AMI are lacking. AMI is due to atherothrombosis, i.e. formation of platelet aggregates (thrombi) on ruptured atherosclerotic plaques. Because platelets release extracellular vesicles (EVs) during thrombus formation, we hypothesized that EVs are a biomarker of atherothrombosis and an early biomarker of AMI.

Venous blood was collected 24 hours (acute phase), 72 hours (hospital discharge) and 6 months (late phase) after AMI from fasting patients (n=60, age 64.5±10.8 years, 68% male), and once from fasting healthy volunteers (n=30, mean age 57.7±6.6 years, 62% male). Flow cytometry (Apogee A60-Micro) was used to determine concentrations of plasma EVs labelled with markers for endothelial cells (CD146), leukocytes (CD45), phosphatidylserine (lactadherin), platelets (CD31, CD61, CD62p), and fibrinogen. Analysis of the 1,224 flow cytometry data files was fully automated with in-house developed software (MATLAB R2018a), enabling automatic flow rate stabilization, application of Rosetta Calibration (Exometry) and Flow-SR for diameter and refractive index determination, size distribution fitting, MESF calibration, fluorescent gate determination, and statistics reporting. To differentiate between EVs and small platelets, only particles <1,000 nm were included. Populations for which an unpaired t-test or one-way ANOVA with Bonferroni correction resulted in p<0.05 were considered significant.

EV concentrations from leukocytes and endothelial cells were lower in patients in the acute AMI phase, compared to healthy volunteers (p<0.05 for both), and increased to the level observed in healthy volunteers in the late phase (p<0.05 for both). Concentrations of PS-exposing EVs and platelet EVs (CD31, CD61) were decreased in the acute AMI phase, compared to the late phase (p<0.05 for all).

We identified decreased concentrations of EVs from leukocytes and endothelial cells as new candidate biomarkers to differentiate patients with atherothrombosis from healthy volunteers. Further, we identified decreased concentrations of PS-exposing EVs and EVs from platelets as new candidate biomarkers to differentiate patients in the acute and late AMI phase. Because the flow rate, fluorescence detectors and scatter detectors of our flow cytometer were calibrated, our data can be compared to future clinical studies, which essential to confirm the clinical utility of EVs as biomarkers of atherothrombosis.

Date: 17th June 2020

Topic: Education Talk

Title: Towards standard analysis and reporting of extracellular vesicle data

Moderators: Edwin van der Pol [1], Estefanía Lozano-Andrés [2]
Amsterdam University Medical Centers, Netherlands [1]
Utrecht University, Netherlands [2]

Speaker: Joshua Welsh, National Cancer Institute

Abstract: TBC

Date: 1st July 2020

Topic: Education Talk

Title: What assay controls provide confidence with your EV flow cytometry analysis?

Moderators: Joshua Welsh [1], John Nolan [2]
National Institutes of Health, USA [1]
Scintillon Institute, La Jolla, USA [2]

Speaker: Joanne Lannigan, Flow Cytometry Support Services, LLC, USA

Abstract: TBC

Previous Events

Date: 20th May 2020

Topic: Educational Talk

Title: Size and refractive index determination of sub-micrometer particles using the flow cytometry scatter ratio (Flow-SR)

Moderators: Joshua Welsh [1], John Nolan [2]
[1] National Institutes of Health, USA. [2] Scintillon Institute, La Jolla, USA

Speaker: Edwin van der Pol, Amsterdam University Medical Centers, Netherlands

Abstract: Flow cytometers measure light scattering signals in arbitrary units, which hampers data interpretation and comparison. Light scattering signals, however, contain valuable information about the size and composition of particles. This information can be assessed by calibration, which means conversion of arbitrary units to standardized measurement units, like diameter in nm. One scatter detector can be calibrated by measuring beads and describing the signals with Mie theory, taking into account the optical configuration of the flow cytometer and the sizes and refractive indices (RIs) of the beads. The RI is an intrinsic property of a particle that depends on the composition and that determines how efficient a particle scatters light. When the RI is known and one scatter detector is calibrated, Mie theory can be used to derive the diameter of extracellular vesicles (EVs) [1]. In this presentation, I will explain that by taking the ratio between side scatter and forward scatter signals, which we named the flow cytometry scatter ratio (Flow-SR), it becomes possible to determine both the diameter and RI of submicrometer particles [2]. Flow-SR enables label-free discrimination between EVs (RI<1.42) and lipoprotein particles (RI>1.45) in plasma and can be used to evaluate the specificity of antibody labels. We have automated Flow-SR and are applying it to analyze data in clinical research studies on EVs (next talk) [3].  [1] De Rond et al. Deriving extracellular vesicle size from scatter intensities measured by flow cytometry. Curr. Protoc. Cytom. e43, 1-14 (2018) [2] van der Pol et al. Absolute sizing and label-free identification of extracellular vesicles by flow cytometry. Nanomedicine 14, 801-10 (2018) [3] Gasecka et al. Ticagrelor attenuates the increase of extracellular vesicles concentrations in plasma after acute myocardial infarction compared to clopidogrel. J. Thromb. Haemost. 18(3), 609-623 (2020)

Date: 6th May 2020

Topic: Educational Talk

Title: MIFlowCyt-EV: a framework for standardized reporting of extracellular vesicle flow cytometry experiments

Moderators: Joanne Lannigan [1] & Joshua Welsh [2]
[1] Flow Cytometry Support Services, LLC, USA [2] National Institutes of Health, USA.

Speaker: John Nolan, Scintillon Institute, La Jolla, USA

Abstract: Extracellular vesicles (EVs) are small, heterogeneous and difficult to measure. Flow cytometry (FC) is a key technology for the measurement of individual particles, but its application to the analysis of EVs and other submicron particles has presented many challenges and has produced a number of controversial results, in part due to limitations of instrument detection, lack of robust methods and ambiguities in how data should be interpreted. The MIFlowCyt-EV framework is an initiative that was developed by a flow cytometry working group of researchers from the international societies for extracellular vesicles, advancement of cytometry and thrombosis and haemostatisis (ISEV-ISAC-ISTH).  The MIFlowCyt-EV framework was designed to be assay agnostic and layout a standard reporting framework for experiments using single extracellular vesicle flow cytometry analysis. This work was recently published as a position paper in the Journal of Extracellular Vesicles.

Date: 22nd April 2020

Topic: Research Talk

Title: Using a Combination of Bead-based and Single EV Imaging Flow Cytometry To Understand EV Heterogeneity

Moderators: Joshua Welsh, National Institutes of Health, USA.

Speaker: André Görgens, Karolinska Institutet, Stockholm, Sweden

Abstract: Extracellular vesicles (EVs) are secreted by all cell types and can be found in all body fluids. They are roughly classified based on their size and origin as exosomes (70-150 nm) and microvesicles (100 nm to 1 µm). However, it is nowadays commonly accepted in the field that there is a much higher degree of EV heterogeneity. The content, protein composition and surface signature of EVs is likely dependent on multiple parameters like the cell’s metabolic or immunological status, and on the cell type releasing them. Accordingly, EVs secreted by different normal cell types or malignant cells also will display distinct surface profiles. We have recently optimized two flow cytometry based methods for EV surface marker analysis, a multiplex bead-based approach which allows robust identification of co-expressed surface marker combinations (Wiklander et al, 2018) and a method using imaging flow cytometry to quantify EV subsets at the single vesicle level (Görgens et al, JEV 2019). Both methods will be briefly introduced and examples for applications in context of heterogeneity will be given.